Digital therapeutics company GAIA has announced the signing of a licensing agreement for attexis with fellow German firm ...

New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, has closed a $215 million Series ...

Danish allergy immunotherapy specialist ALK Abello today posted financial results for the third quarter of 2024, which ...

Syncona has launched Slingshot Therapeutics with an initial $15 million investment through its Syncona Accelerator initiative ...

Pharma major Bristol Myers Squibb (NYSE: BMY) and US biotech Cabaletta Bio are set to present promising Phase I data on ...

Adaptimmune’s Phase II trial of lete-cel showed a 42% response rate in synovial sarcoma and MRCLS, with strong median ...

Sino-American firm Insilico Medicine has shown the potential not just of its pipeline and lead candidate by presenting ...

Apollo Therapeutics and Sunshine Lake Pharma have signed a license deal for APL-18881, a bi-specific fusion protein targeting ...

Shares of US genetic meds company MeiraGTx Holdings were up 7% at $7.12 in early trading after it announced important ...

Gilead Sciences has announced new data from its pivotal Phase III PURPOSE 2 trial providing further details on the efficacy, ...

Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...

Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...